Nav: Home

Repairing leaky valve improves heart failure patients' quality of life

March 18, 2019

NEW ORLEANS (March 17, 2019) -- Patients with heart failure and a leaking heart valve reported feeling better and experiencing fewer heart failure symptoms if they underwent a procedure to repair their valve than patients who received standard treatment alone, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

The findings are the latest to come from the COAPT trial, which investigated the use of a procedure called transcatheter mitral valve repair (TMVR) in patients with secondary mitral regurgitation, a condition where the mitral valve does not close properly due to problems with the heart's chambers. In 2018, COAPT researchers reported that patients undergoing TMVR had significantly better rates of survival at two years compared with those receiving standard medical therapy. For the new study, researchers further analyzed data from the trial to determine whether the valve repair also improved patients' quality of life.

"In patients with heart failure and secondary mitral regurgitation, TMVR resulted in early, substantial and sustained improvement in health status compared with standard care," said Suzanne Arnold, MD, a cardiologist at Saint Luke's Mid America Heart Institute, associate professor of medicine at the University of Missouri-Kansas City and the study's lead author. "These outcomes are incredibly important to patients. Showing that TMVR improves patients' symptoms and quality of life adds further support to the use of TMVR in these patients."

Heart failure, a condition in which the heart cannot pump enough blood to meet the body's needs, affects about 5 million people in the United States. It is estimated that at least a quarter of heart failure patients also have secondary mitral valve regurgitation, which allows blood to flow backward through the mitral valve and further reduces the heart's ability to pump blood. People with both conditions commonly suffer symptoms such as shortness of breath, swelling and fatigue.

COAPT enrolled 614 patients treated at 78 medical centers in the U.S. and Canada and randomly assigned them to receive TMVR or standard medical therapy, which typically includes diuretics, beta blockers, other medications, and sometimes cardiac resynchronization therapy. All participants had heart failure and moderate to severe secondary mitral regurgitation at the start of the trial. Researchers assessed participants' quality of life with the Kansas City Cardiomyopathy Questionnaire (KCCQ), a tool designed to assess the symptoms, functional limitations, social limitations and quality of life of people with heart failure.

At the start of the trial, participants scored 52 out of 100 on the KCCQ summary score, on average, which reflects a relatively poor quality of life. Patients' heart failure symptoms significantly limited their daily activities, causing shortness of breath or fatigue when walking on level ground or doing light housework, Arnold said.

After one month, patients who underwent TMVR reported a 16-point greater improvement in their average KCCQ score compared with those on standard therapy, an improvement considered moderate to large. Patients potentially still had shortness of breath or fatigue when walking briskly or up an incline but were no longer limited in their ability to do less vigorous activities, such as shopping or walking at a normal pace.

By the end of two years, those undergoing TMVR had an average KCCQ score 13 points higher, on average, than those on standard therapy.

"The durability of the finding was a bit surprising given that these patients had pretty severe heart failure at baseline," Arnold said. "You might expect that the benefit might wane over time, and the fact that we didn't see much reduction over time was encouraging."

Although deaths were common in both treatment groups owing to advanced age, comorbidities and underlying heart failure, a higher proportion of patients who were randomized to TMVR were alive with significant improvement in health status at every follow-up time point. For example, at two years, 36 percent of patients treated with TMVR were alive with a moderate improvement in health status compared with only 17 percent in the standard care arm.

The study was limited by the fact that it was not a blinded trial; patients knew if they had undergone valve repair. In addition, because a relatively large proportion of patients died before the end of the two-year follow-up, the loss of the more severely ill patients, who likely had the poorest quality of life, may have biased the average quality of life over time in a slightly upward direction. It is also unclear whether the results are generalizable beyond the specific patient group included in the trial, Arnold said.
The study was funded by Abbott.

This study was simultaneously published online in the Journal of the American College of Cardiology at the time of presentation.

The ACC's Annual Scientific Session will take place March 16-18, 2019, in New Orleans, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC19 for the latest news from the meeting.

The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its more than 52,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit

American College of Cardiology

Related Heart Failure Articles:

New hope for treating heart failure
Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.
Activated T-cells drive post-heart attack heart failure
Chronic inflammation after a heart attack can promote heart failure and death.
ICU care for COPD, heart failure and heart attack may not be better
Does a stay in the intensive care unit give patients a better chance of surviving a chronic obstructive pulmonary disease (COPD) or heart failure flare-up or even a heart attack, compared with care in another type of hospital unit?
Tissue engineering advance reduces heart failure in model of heart attack
Researchers have grown heart tissue by seeding a mix of human cells onto a 1-micron-resolution scaffold made with a 3-D printer.
Smoking may lead to heart failure by thickening the heart wall
Smokers without obvious signs of heart disease were more likely than nonsmokers and former smokers to have thickened heart walls and reduced heart pumping ability.
After the heart attack: Injectable gels could prevent future heart failure (video)
During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells in the heart.
Heart failure after first heart attack may increase cancer risk
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study today in the Journal of the American College of Cardiology.
Scientists use 'virtual heart' to model heart failure
A team of researchers have created a detailed computational model of the electrophysiology of congestive heart failure, a leading cause of death.
Increase in biomarker linked with increased risk of heart disease, heart failure, death
In a study published online by JAMA Cardiology, Elizabeth Selvin, Ph.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues examined the association of six-year change in high-sensitivity cardiac troponin T with incident coronary heart disease, heart failure and all-cause mortality.
1 in 4 patients develop heart failure within 4 years of first heart attack
One in four patients develop heart failure within four years of a first heart attack, according to a study in nearly 25,000 patients presented today at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure by Dr.

Related Heart Failure Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".